See more : Intouch Holdings Public Company Limited (SWTF.F) Income Statement Analysis – Financial Results
Complete financial analysis of Athenex, Inc. (ATNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athenex, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- International Isotopes Inc. (INIS) Income Statement Analysis – Financial Results
- Fusion Micro Finance Limited (FUSION.NS) Income Statement Analysis – Financial Results
- Bio-Works Technologies AB (publ) (BIOWKS.ST) Income Statement Analysis – Financial Results
- Wuhan Lincontrol Automotive Electronics Co., Ltd. (688667.SS) Income Statement Analysis – Financial Results
- High Co. SA (HCO.PA) Income Statement Analysis – Financial Results
Athenex, Inc. (ATNX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.athenex.com
About Athenex, Inc.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 102.82M | 120.18M | 144.39M | 101.23M | 89.10M | 38.04M | 20.55M | 13.94M |
| Cost of Revenue | 76.12M | 82.41M | 95.36M | 69.62M | 47.01M | 25.12M | 19.72M | 13.15M |
| Gross Profit | 26.70M | 37.78M | 49.04M | 31.61M | 42.10M | 12.92M | 833.00K | 791.00K |
| Gross Profit Ratio | 25.97% | 31.43% | 33.96% | 31.23% | 47.24% | 33.96% | 4.05% | 5.67% |
| Research & Development | 51.76M | 80.20M | 75.90M | 84.39M | 119.91M | 76.80M | 60.62M | 24.46M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 44.88M | 72.55M | 96.86M | 66.75M | 49.01M | 46.11M | 25.96M | 27.04M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 19.71M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 96.64M | 152.75M | 172.76M | 151.14M | 168.91M | 122.91M | 86.58M | 51.50M |
| Cost & Expenses | 172.76M | 235.16M | 268.11M | 220.76M | 215.92M | 148.03M | 106.30M | 64.65M |
| Interest Income | 363.00K | 227.00K | 874.00K | 1.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.84M | 20.74M | 11.22M | 6.95M | 1.79M | 5.91M | 1.89M | 1.00K |
| Depreciation & Amortization | 363.00K | 227.00K | 874.00K | 1.88M | 3.27M | 3.67M | 2.03M | 888.00K |
| EBITDA | -69.57M | -114.75M | -122.85M | -117.65M | -112.28M | -121.50M | -84.06M | -49.77M |
| EBITDA Ratio | -67.66% | -95.48% | -85.08% | -116.22% | -126.01% | -319.38% | -409.05% | -356.89% |
| Operating Income | -69.94M | -114.98M | -123.72M | -119.53M | -126.82M | -109.99M | -85.75M | -50.71M |
| Operating Income Ratio | -68.02% | -95.67% | -85.69% | -118.08% | -142.33% | -289.11% | -417.24% | -363.65% |
| Total Other Income/Expenses | -28.69M | -89.93M | -20.62M | -5.07M | -1.79M | -21.32M | -2.42M | -1.00K |
| Income Before Tax | -98.63M | -204.91M | -144.35M | -124.61M | -128.61M | -131.31M | -88.17M | -50.71M |
| Income Before Tax Ratio | -95.92% | -170.50% | -99.97% | -123.09% | -144.34% | -345.16% | -429.04% | -363.66% |
| Income Tax Expense | 347.00K | -10.60M | 4.09M | 928.00K | 100.00K | 85.00K | -265.00K | -54.00K |
| Net Income | -98.98M | -194.31M | -148.43M | -125.53M | -117.44M | -131.17M | -87.72M | -50.60M |
| Net Income Ratio | -96.26% | -161.68% | -102.80% | -124.01% | -131.81% | -344.79% | -426.82% | -362.88% |
| EPS | -15.13 | -37.39 | -34.89 | -33.90 | -36.40 | -45.06 | -41.51 | -21.77 |
| EPS Diluted | -15.13 | -37.39 | -34.89 | -33.90 | -36.40 | -45.06 | -41.51 | -21.77 |
| Weighted Avg Shares Out | 6.54M | 5.20M | 4.25M | 3.70M | 3.23M | 2.91M | 2.11M | 2.32M |
| Weighted Avg Shares Out (Dil) | 6.54M | 5.20M | 4.25M | 3.70M | 3.23M | 2.91M | 2.11M | 2.32M |
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
Athenex to Participate in Truist Securities Cell Therapy Symposium
Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy
Athenex, Inc.'s (ATNX) CEO Johnson Lau on Q1 2022 Results - Earnings Call Transcript
Athenex Provides First Quarter 2022 Financial Results and Business Update
Athenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASGCT 25th Annual Meeting
Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022
Source: https://incomestatements.info
Category: Stock Reports